Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a conference call to discuss these results. Our investors relations team remains available ...

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech / pharma companiesAddressing large and ...

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasd ...

Press Democrat readers share their thoughts on the president, the federal shutdown, resistance movements and Democrats ...

Mary E. Brunkow Ph.D., a 1983 graduate of UW who now works in Seattle, won the Nobel Prize in Physiology or Medicine. News of ...

Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and gro ...

After two days full of live demos and pitches, it's time to announce the five finalists at this year's Startup Battlefield.

Agencies are posting on their websites, "This is the Democrat's fault ... I thought this is a really incredible moment in ...

EPFL scientists have found that changing the "packaging" of DNA in neurons can turn memories on or off in mice.Our ...

SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative ...